Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.31 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.30 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12038058 | 0.93 | FOLH1 (0.35) | FOLH1SIRT2SIRT1HDAC4MEF2D | |
| SCHEMBL277717 | 0.91 | SIRT2 (0.35) | FOLH1SIRT2SIRT1HDAC4MEF2D | |
| SCHEMBL14753625 | 0.90 | FOLH1 (0.34) | FOLH1SIRT2SIRT1HDAC4MEF2D | |
| SCHEMBL13311706 | 0.88 | SIRT2 (0.34) | FOLH1SIRT2SIRT1HDAC4MEF2D | |
| SCHEMBL16441086 | 0.87 | FOLH1 (0.32) | FOLH1SIRT2SIRT1OPRK1 | |
| SCHEMBL12692608 | 0.87 | FOLH1 (0.36) | FOLH1SIRT2SIRT1HDAC4MEF2D | |
| SCHEMBL14753619 | 0.85 | FOLH1 (0.36) | FOLH1SIRT2SIRT1HDAC4MEF2D | |
| SCHEMBL277487 | 0.85 | SIRT2 (0.40) | FOLH1SIRT2SIRT1HDAC4MEF2D | |
| SCHEMBL13339580 | 0.84 | SIRT2 (0.36) | FOLH1SIRT2SIRT1HDAC4MEF2D | |
| SCHEMBL12417525 | 0.84 | SIRT2 (0.37) | SIRT2SIRT1HDAC4MEF2DEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | FOLH1 31/4885SIRT2 4150/4885SIRT1 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.